The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma

International Journal of Oncology

Volumn 27, Issue 6, 2005, Pages 1707-1715

  Lagerstedt, K K ^a   Kressner, U ^b   Lonnroth C ^a   Nordgren, S ^a   Lundholm, K ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UDDEVALLA HOSPITAL   (Sweden)

Author keywords

Allelic imbalance; Colorectal cancer; LOH; P53

Indexed keywords

MICROSATELLITE DNA; PROTEIN P53;

ADULT; AGED; ALLELIC IMBALANCE; ANALYSIS OF VARIANCE; ARTICLE; CANCER STAGING; COLORECTAL TUMOR; DISEASE COURSE; FEMALE; GENETICS; HETEROZYGOSITY LOSS; HUMAN; MALE; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ALLELIC IMBALANCE; ANALYSIS OF VARIANCE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33644825802     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R and Vogelstein B: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221, 1989.
2. Forslund A and Lundholm K: The role of p53 in tumor progression and prognosis in patients with primary colorectal cancer - an update. Recent Res Dev Cancer 4: 263-282, 2002.
3. Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, Sarbia M, Borchard F, Greschniok A, Gruenagel HH, Porschen R and Gregor M: Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis 19: 23-42, 2004.
4. Ohue M, Tomita N, Monden T, Fujita M, Fukunaga M, Takami K, Yana I, Ohnishi T, Enomoto T, Inoue M, et al: A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res 54: 4798-4804,1994.
5. Matlashewski G, Lamb P, Pirn D, Peacock J, Crawford L and Benchimol S: Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J 3: 3257-3262,1984.
6. Diep CB, Teixeira MR, Thorstensen L, Wiig JN, Eknaes M, Nesland JM, Giercksky KE, Johansson B and Lothe RA: Genome characteristics of primary carcinomas, local recurrences, carcinomatoses and liver metastases from colorectal cancer patients. Mol Cancer 3: 6-14,2004.
7. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
8. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767,1990.
9. Delattre O, Olschwang S, Law DJ, Melot T, Remvikos Y, Salmon RJ, Sastre X, Validire P, Feinberg AP and Thomas G: Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2: 353-356,1989.
10. Douglas EJ, Fiegler H, Rowan A, Halford S, Bicknell DC, Bodmer W, Tomlinson IP and Carter NP: Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res 64: 4817-4825, 2004.
11. Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM and Boland CR: Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63: 1608-1614,2003.
12. Risio M, Casorzo L, Chiecchio L, De Rosa G and Rossini FP: Deletions of 17p are associated with transition from early to advanced colorectal cancer. Cancer Genet Cytogenet 147: 44-49, 2003.
13. Vousden KH and Prives C: P53 and prognosis: new insights and further complexity. Cell 120: 7-10,2005.
14. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B and Lindmark G. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17: 593-599,1999.
15. Forslund A, Kressner U, Lönnroth C, Andersson M, Lindmark G and Lundholm K: P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH. Int J Oncol 21: 409-415, 2002.
16. Yang Y, Forslund A, Remotti H, Lönnroth C, Andersson M, Brevinge H, Svanberg E, Lindner P, Hafstrom L, Naredi P and Lundholm K: P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 91: 727-736, 2001.
17. Forslund A, Lönnroth C, Andersson M, Brevinge H and Lundholm K: Mutations and allelic loss of p53 in primary tumor DNA from potential cured patients with colorectal carcinoma. J Clin Oncol 19: 2829-2836, 2001.
18. Forslund A, Kressner U, Lindmark G, Inganas M and Lundholm K: Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas. Int J Oncol 19:501-506,2001.
19. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J: The p53 gene in breast cancer: rognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182, 1996.
20. Stahl S, Hultman T, Olsson A, Moks T and Uhlen M: Solid phase DNA sequencing using the biotin-avidin system. Nucleic Acids Res 16: 3025-3038,1988.
21. Lagerkvist A, Stewart J, Lagerstrom-Fermer M and Landegren U: Manifold sequencing: efficient processing of large sets of equencing reactions. Proc Natl Acad Sci USA 91: 2245-2249, 1994.
22. Hahn M, Fislage R and Pingoud A: Polymorphism of the pentanucleotide repeat d(AAAAT) within intron 1 of the human tumor suppressor gene p53 (17pl3.1). Hum Genet 95: 471-472, 1995.
23. GDB: GDB (TM) Human Genome Database Do. Human Genome Database. RTI International, 1990.
24. Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS and Lothe RA: Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 127: 64-70, 2001.
25. Ensembl: Ensembl Genome Browser, www.Ensembl.org
26. Woods DB and Vousden KH: Regulation of p53 function. Exp Cell Res 264: 56-66, 2001.
27. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526,1992.
28. Risques RA, Moreno V, Ribas M, Marcuello E, Capella G and Peinado MA: Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer. Cancer Res 63: 7206-7214,2003.
29. Rajagopalan H, Nowak MA, Vogelstein B and Lengauer C: The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 3: 695-701, 2003.
30. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K and Quirke P: DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360: 1381-1391,2002.
31. Leslie A, Pratt NR, Gillespie K, Sales M, Kernohan NM, Smith G, Wolf CR, Carey FA and Steele RJ: Mutations of APC, K-ras and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res 63: 4656-4661,2003.
32. Reisman D, Greenberg M and Rotter V: Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc Natl Acad Sci USA 85: 5146-5150 1988.
33. Matsumoto N, Yoshida T, Yamashita K, Numata Y and Okayasu I: Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma. Br J Cancer 89:707-712,2003.
34. Iacopetta B: TP53 mutation in colorectal cancer. Hum Mutat 21: 271-276,2003.
35. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, Validire P, Muleris M, Girodet J, Salmon RJ, et at Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102: 1136-1141, 1992.
36. Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO and Lothe RA: Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 21: 820-829, 2003.
37. Guimaraes DP and Hainaut P: TP53: a key gene in human cancer. Biochimie 84: 83-93, 2002.